Dan Hardy

Maternal, Fetal & Newborn Health Dr. Dan Hardy


Scientist, Division of Maternal, Fetal & Newborn Health, Children's Health Research Institute
Associate Professor, Department of Obstetrics & Gynaecology and Physiology & Pharmacology, Schulich School of Medicine & Dentistry, Western University

How my research helps children

My work further emphasizes the importance of a healthy pregnancy given that adverse events during fetal and neonatal development can have both short-term effects on children and long-term (i.e. CVD and diabetes) as adults.  These adverse in utero events include under-nutrition and low oxygen, and both lead to intrauterine growth restriction (IUGR).  Specifically, my recent research has identified that impaired fetal development can lead to elevated circulating cholesterol in young and old rat offspring.  Recent focus in the lab involves how perinatal intervention (e.g. diet) in IUGR offspring can prevent the development of these long-term adult disease processes.


Current Research

To date, Dr. Hardy has recently submitted a manuscript in Moledular Endocrinology entitled “Maternal Protein Restriction Elevates Cholesterol in Adult Rat Offspring Due to Repressive Histone Modifications at the Promoter of Hepatic Cholesterol 7α-Hydroxylase.”  He was also guest editor for an upcoming issue of Seminars in Reproduction focused on the "Early Life Origins of Adult Diseases."

Research Team

Dr. Hardy’s lab consists of four graduate students (three MSc and one PhD), an undergraduate student, and a laboratory/animal technician.  Dr. Hardy anticipates recruiting an additional MSc student and a Physiology and Pharmacology student in the fall of 2013.  Moreover, his laboratory was recently renovated due to a CFI award with Dr. Tim Regnault.  To date, Dr. Hardy continues to collaborate with many members of CHRI including Drs. Tim Regnault, Dean Betts, Bryan Richardson and Edith Arany.

Future Research Plans

In addition to Dr. Hardy’s interests in the role of nuclear receptors in fetal programming (due to nutrition and hypoxia), his lab has also identified some of the epigenetic mechanisms involved. Looking forward, Dr. Hardy’s lab is interested in how intervention in neonatal life may impair or prevent on the onset of adult diseases in IUGR offspring.  Furthermore, Dr. Hardy has a keen interest in how microRNAs might be involved in regulating organ growth in prenatal and postnatal life. Collaborations with experts in the field at the University of Florida are helping him address these important and interesting questions.

Awards & Grants

Awards & Grants

Funding in support "Telomerase Therapy for Intrauterine Growth Restriction" – Awarded by Western Strategic Support for CIHR Success

Academic Enrichment Fund (AEF) – Awarded by Obstetrics & Gynaecology, UWO

Perkin-Elmer Early Research Award – Awarded by Perinatal Research Society

Funding in support of "Molecular Mechanisms Underlying the In utero Origins of Hypercholesterolemia" – Awarded by Canadian Institute of Health Research (CIHR)

Funding in support of "Preventing Hypercholesterolemia by Neonatal Intervention with LXR Agonists" – Awarded by Lawson Health Research Institute

Endocrine Scholar Award – Awarded by The Endocrine Society

Faculty of Science Alumni of Honour Award – Awarded by University of Waterloo

Sigma Xi Award – Awarded by University of Texas Southwestern Medical Center

Post doctoral Fellowship – Awarded by Susan G. Komen Breast Cancer Foundation

CIHR New Investigator Award in support of “The Molecular Mechanisms for Fetal Programming”– Awarded by SickKids Foundation

Funding in support of “The Role of Nuclear Receptors in Fetal Programming” – Awarded by Natural Science and Engineering Council of Canada (NSERC)

Funding in support of “Measuring Changes in Nuclear Receptor Binding During Fetal and Neonatal Development Using ChIP” – Awarded by Natural Science and Engineering Council of Canada

Funding in support of “A laboratory for investigating the Role of Fetal Programming in Metabolic Syndrome” – Awarded by Canadian Foundation for Innovation (CFI)

Academic Enrichment Fund – Awarded by The University of Western Ontario

Recent Publications


Nutritional Mismatch in Postnatal Life of Low Brith Weight Rat Offspring Leads to Elevated Hepatic Cyp3A and Cyp2C Activity in Adulthood
Sohi G, Barry EJ, Velonosi TJ, Urquhart BL, Hardy DB
Drug Metabolism and Disposition. 2014; 42:221-228

Enhanced trimethylation of histone H3 mediates impaired expression of hepatic glucose-6-phosphatase (G6Pase) expression in offspring from rat dams exposed to hypoxia during pregnancy
Osumek JE, Revesz A, Morton JS, Davidge ST, Hardy DB
Reproductive Sciences. 2014; 21(1):112-121

Maternal protein restriction leads to disruption of hepatic gluconeogenic gene expression in adult male offspring due to impaired expression of the liver X receptor
Vo T, Revesz A, Sohi G, Ma N, Hardy DB
J of Endocrinology. 2013 June 1; 218(1):85-97

Nutritional Mismatch in Postnatal Life of Low Birth Weight Rat Offspring Leads to Increased Phosphorylation of Hepatic Eukaryotic Initiation Factor 2{alpha} in Adulthood
Sohi G, Revesz A, Hardy DB
Metabolism. 2013; 62:1367-1374

Umbilical Cord Cytokines/Chemokines and the Impact of Labor Events in Low Risk Term Pregnancies
Chan CJ, Summers KL, Chan N, Hardy DB, Richardson BS
Early Human Development. 2013 August

Protein restriction during early life in rats alters pancreatic GABAa receptor subunit expression and glucagon secretion in adulthood
Durst, MA, Lux-Lantos VA, Hardy DB, Arany EJ, and Hill DJ
Canadian Journal of Diabetes. 2012; 36(3):100-107

Molecular Mechanisms Underlying the Fetal Programming of Adult Disease
Vo T, Hardy DB
J Cell Communication and Signaling. 2012; 6:139-153

The Fetal Origins of the Metabolic Syndrome: Can we Intervene?
Ma N, Hardy DB
J Pregnancy; doi:10.115/2012/482690

The Developmental Origins of Health and Disease: Today's Perspectives and Tomorrow's Challenges.
Hardy DB
Semin Reprod Med. 2011;29(3):171-172

Maternal Protein Restriction Elevates Cholesterol in Adult Rat Offspring Due to Repressive Changes in Histone Modifications at the Cholesterol 7a-Hydroxylase Promoter.
Sohi G, Marchand K, Revesz A, Arany E, Hardy DB
Mol Endocrinol. 2011 Mar 3

Sp1 Response Elements within the MAPK Phosphatase-1 (MKP-1/DUSP1) Promoter Mediate Progesterone Receptor (PR) Induced MKP-1 Expression in Breast Cancer Cells
Chien CC, Hardy DB, Mendelson CR
Journal of Biological Chemistry. 2011; 6,286(50):43091-102

Permanent implications of IUGR on cholesterol homeostasis
Sohi G, Revesz A, Hardy DB
Semin Reprod Med. 2011;29(3):246-256

Gonadotropin releasing hormone antagonists suppress aromatase and anti-Müllerian hormone expression in human granulosa cells
Winkler N, Bukulmez O, Hardy DB, Carr BR
Fertil Steril. 2009 Nov 5

Antisense transcripts are targets for activating small RNAs
Schwartz JC, Younger ST, Nguyen NB, Hardy DB, Monia BP, Corey DR, Janowski BA
Nat Struct Mol Biol. 2008 Aug;15(8):842-8

Androstenedione up-regulation of endometrial aromatase expression via local conversion to estrogen: potential relevance to the pathogenesis of endometriosis.
Bukulmez O, Hardy DB, Carr BR, Auchus RJ, Toloubeydokhti T, Word RA, Mendelson CR
J Clin Endocrinol Metab. 2008 Sep;93(9):3471-7

Progesterone receptor inhibits aromatase and inflammatory response pathways in breast cancer cells via ligand-dependent and ligand-independent mechanisms.
Hardy DB, Janowski BA, Chen CC, Mendelson CR
Mol Endocrinol. 2008 Aug;22(8):1812-24.

Inflammatory status influences aromatase and steroid receptor expression in endometriosis
Bukulmez O, Hardy DB, Carr BR, Word RA, Mendelson CR
Endocrinology. 2008 Mar;149(3):1190-204

Progesterone receptor expression is a marker for early stage breast cancer: implications for progesterone receptor as a therapeutic tool and target
Coyle YM, Xie XJ, Hardy DB, Ashfaq R, Mendelson CR
Cancer Lett. 2007 Dec 18;258(2):253-61.

Activating gene expression in mammalian cells with promoter-targeted duplex RNAs.
Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, Corey DR.
Nat Chem Biol. 2007 Mar;3(3):166-73

Additional publications



Phone: (519) 661-2111, x84238
Fax: (519) 661-3827
Email: Daniel [dot] Hardy [at] schulich [dot] uwo [dot] ca
Website: http://www.uwo.ca/physpharm/faculty/hardy_daniel.html

(Please note: CHRI is not responsible for the content of any external sites - links will open in new window)